SCHEMBL4711636

SCHEMBL4711636

Cc1cccc(Cn2c(C(=O)O)cc3c2ccc(=O)n3-c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 2/20 0.46
THRB P10828 2/20 0.46
ERCC5 P28715 2/20 0.46
FEN1 P39748 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
CCR2 P41597 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43
GPR35 Q9HC97 1/20 0.43
RGS4 P49798 1/20 0.42
RGS8 P57771 1/20 0.42
ECE1 P42892 1/20 0.42
BRD4 O60885 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714667 0.91 PLA2G10 (0.47) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL4789434 0.88 ALDH1A1 (0.53) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL4714198 0.87 ALDH1A1 (0.45) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL5119050 0.86 CCR2 (0.62) MAPTERCC5CCR2GPR35
SCHEMBL4715116 0.85 CCR2 (0.55) MAPTCCR2TP53GPR35RGS4
SCHEMBL4714035 0.84 CCR2 (0.48) CCR2GPR35
SCHEMBL4717315 0.81 SPHK2 (0.42) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL4716102 0.80 MAPT (0.57) MEN1KMT2AALDH1A1L3MBTL1MAPT
SCHEMBL4714560 0.79 CCR2 (0.52) CCR2
SCHEMBL4711188 0.78 BRD4 (0.53) ALDH1A1MAPTTHRBERCC5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MEN1 4819/4885KMT2A 2241/4885ALDH1A1 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.